Compare SNY & NTES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNY | NTES |
|---|---|---|
| Founded | 1994 | 1997 |
| Country | France | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.7B | 77.8B |
| IPO Year | 2001 | 2002 |
| Metric | SNY | NTES |
|---|---|---|
| Price | $46.64 | $99.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 32 |
| Target Price | $54.92 | ★ $155.79 |
| AVG Volume (30 Days) | ★ 4.2M | 927.5K |
| Earning Date | 10-30-2026 | 11-19-2026 |
| Dividend Yield | ★ 5.25% | 2.78% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.97 | $3.17 |
| Revenue Next Year | $6.77 | $8.59 |
| P/E Ratio | ★ $6.14 | $79.88 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.07 | $104.63 |
| 52 Week High | $50.61 | $149.11 |
| Indicator | SNY | NTES |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 25.09 |
| Support Level | $45.95 | N/A |
| Resistance Level | $48.57 | $120.60 |
| Average True Range (ATR) | 0.86 | 2.82 |
| MACD | -0.20 | -2.21 |
| Stochastic Oscillator | 40.49 | 3.43 |
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Founded in the late 1990s as an internet portal, NetEase has evolved into China's second-largest online gaming company. Its early success was anchored by the massively multiplayer online role-playing game Fantasy Westward Journey, which laid the foundation for a durable franchise strategy. Over the past decade, the company has expanded its portfolio with successful titles such as Justice, Identity V, Naraka: Bladepoint, and Eggy Party, all of which continue to maintain sizable and engaged player bases.In addition to its in-house development capabilities, NetEase partners with global IP holders such as Microsoft and Marvel to develop and publish titles based on established franchises, including World of Warcraft, Diablo Immortal, and Marvel Rivals, further strengthening its global presence.